Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
- Author:
Wei CHEN
1
;
Li-Hong ZHANG
;
Hong-Ying LIU
;
Xin-Bo ZHOU
;
Li-Li WANG
Author Information
1. Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
11-beta-Hydroxysteroid Dehydrogenase Type 1;
genetics;
metabolism;
Adipose Tissue, White;
drug effects;
Animals;
Animals, Newborn;
Blood Glucose;
metabolism;
Body Weight;
drug effects;
Drug Synergism;
Eating;
drug effects;
Fenofibrate;
pharmacology;
Hypoglycemic Agents;
pharmacology;
Hypolipidemic Agents;
pharmacology;
Insulin Resistance;
Lipids;
blood;
Lipoprotein Lipase;
genetics;
metabolism;
Liver;
drug effects;
Metabolic Syndrome;
chemically induced;
metabolism;
pathology;
Mice;
Mice, Inbred ICR;
RNA, Messenger;
metabolism;
Sodium Glutamate;
Thiazolidinediones;
pharmacology
- From:
Acta Pharmaceutica Sinica
2010;45(11):1459-1466
- CountryChina
- Language:English
